专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09155790B2 Methods and compositions for modulating ocular damage 有权
标题翻译：用于调节眼部损伤的方法和组合物
公开(公告)号：US09155790B2
公开(公告)日：2015-10-13
申请号：US13698518
申请日：2011-05-20
申请人： Tongalp H. Tezel , Henry J. Kaplan , Robert A. Mitchell , John O. Trent
发明人： Tongalp H. Tezel , Henry J. Kaplan , Robert A. Mitchell , John O. Trent
IPC分类号： A61K31/517 , A61K39/395 , A61K31/505 , A61K31/53 , A61K45/06
CPC分类号： A61K39/3955 , A61K31/505 , A61K31/53 , A61K45/06 , A61K2300/00
摘要： Methods for modulating eye damage associated with a disease or disorder, and/or damage incident to trauma including but not limited to trauma associated with ocular surgery are provided. In some embodiments, the methods include administering an effective amount of a modulator of a migration inhibitory factor (MIF) polypeptide biological activity to a subject. Also provided are methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of an ocular disease, and methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of scarring and/or other consequence of wound healing incident to ocular surgery, as well as modulating the survival, function, and/or differentiation of engrafted cells that can be employed as part of tissue engineering procedures to correct structural, functional, and/or cellular defects of the eye.
摘要翻译：提供了用于调节与疾病或病症相关的眼睛损伤和/或损伤事件的方法，包括但不限于与眼部手术相关的创伤。在一些实施方案中，所述方法包括向受试者施用有效量的迁移抑制因子（MIF）多肽生物活性的调节剂。还提供了用于调节延缓发作和/或预防眼部疾病发展的严重性的方法，以及调节延缓发作和/或抑制和/或预防眼部疾病的发生的严重性的方法伤口愈合和/或眼部手术引起的伤口愈合的其他结果，以及调节可以用作组织工程程序的一部分以修正结构，功能和/或细胞的移植细胞的存活，功能和/或分化眼睛的缺陷。

2. 发明申请

US20130177552A1 METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE 有权
标题翻译：调节眼损伤的方法和组合物
公开(公告)号：US20130177552A1
公开(公告)日：2013-07-11
申请号：US13698518
申请日：2011-05-20
申请人： Tongalp H. Tezel , Henry J. Kaplan , Robert A. Mitchell , John O. Trent
发明人： Tongalp H. Tezel , Henry J. Kaplan , Robert A. Mitchell , John O. Trent
IPC分类号： A61K39/395 , A61K31/505
CPC分类号： A61K39/3955 , A61K31/505 , A61K31/53 , A61K45/06 , A61K2300/00
摘要： Methods for modulating eye damage associated with a disease or disorder, and/or damage incident to trauma including but not limited to trauma associated with ocular surgery are provided. In some embodiments, the methods include administering an effective amount of a modulator of a migration inhibitory factor (MIF) polypeptide biological activity to a subject. Also provided are methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of an ocular disease, and methods for modulating the severity of delaying the onset of and/or inhibiting and/or preventing the development of scarring and/or other consequence of wound healing incident to ocular surgery, as well as modulating the survival, function, and/or differentiation of engrafted cells that can be employed as part of tissue engineering procedures to correct structural, functional, and/or cellular defects of the eye.
摘要翻译：提供了用于调节与疾病或病症相关的眼睛损伤和/或损伤事件的方法，包括但不限于与眼部手术相关的创伤。在一些实施方案中，所述方法包括向受试者施用有效量的迁移抑制因子（MIF）多肽生物活性的调节剂。还提供了用于调节延缓发作和/或预防眼部疾病发展的严重性的方法，以及调节延缓发作和/或抑制和/或预防眼部疾病的发生的严重性的方法伤口愈合和/或眼部手术引起的伤口愈合的其他结果，以及调节可以用作组织工程程序的一部分以修正结构，功能和/或细胞的移植细胞的存活，功能和/或分化眼睛的缺陷。

3. 发明申请

US20110159016A1 HEMOGLOBIN-BASED METHODS FOR PROPHYLAXIS, DIAGNOSIS AND/OR TREATMENT OF RETINAL DISORDERS 审中-公开
标题翻译：基于HEMOGLOBIN的预防性疾病的方法，诊断和/或治疗反应性疾病
公开(公告)号：US20110159016A1
公开(公告)日：2011-06-30
申请号：US13035272
申请日：2011-02-25
申请人： Tongalp H. Tezel , Henry J. Kaplan , Jon Klein
发明人： Tongalp H. Tezel , Henry J. Kaplan , Jon Klein
IPC分类号： A61K39/395 , G01N33/72 , A61K38/18 , A61P27/02
CPC分类号： G01N33/723 , G01N2800/164
摘要： The presently disclosed subject matter provides methods of diagnosing retinal disorders in subjects by measuring hemoglobin and modified hemoglobin in the subjects. The presently disclosed subject matter further provides methods of treating retinal disorders in subjects by decreasing hypoxia in retinal tissue of the subjects through modulation of hemoglobin levels and activities in the retinal tissue.
摘要翻译：目前公开的主题提供了通过测量受试者中的血红蛋白和修饰的血红蛋白来诊断受试者的视网膜疾病的方法。目前公开的主题还提供了通过调节血红蛋白水平和视网膜组织中的活性来减少受试者的视网膜组织中的缺氧来治疗受试者的视网膜疾病的方法。

4. 发明申请

US20090053816A1 HEMOGLOBIN-BASED METHODS FOR PROPHYLAXIS, DIAGNOSIS AND/OR TREATMENT OF RETINAL DISORDERS 审中-公开
标题翻译：基于HEMOGLOBIN的预防性疾病的方法，诊断和/或治疗反应性疾病
公开(公告)号：US20090053816A1
公开(公告)日：2009-02-26
申请号：US12294409
申请日：2007-03-26
申请人： Tongalp H. Tezel , Henry J. Kaplan , Jon Klein
发明人： Tongalp H. Tezel , Henry J. Kaplan , Jon Klein
IPC分类号： G01N33/72 , C12Q1/00 , A61K38/00 , A61K39/395 , A61P27/00 , A61B5/05 , A61B17/20
CPC分类号： G01N33/723 , G01N2800/164
摘要： The presently disclosed subject matter provides methods of diagnosing retinal disorders in subjects by measuring hemoglobin and modified hemoglobin in the subjects. The presently disclosed subject matter further provides methods of treating retinal disorders in subjects by decreasing hypoxia in retinal tissue of the subjects through modulation of hemoglobin levels and activities in the retinal tissue.
摘要翻译：目前公开的主题提供了通过测量受试者中的血红蛋白和修饰的血红蛋白来诊断受试者的视网膜疾病的方法。目前公开的主题还提供了通过调节血红蛋白水平和视网膜组织中的活性来减少受试者的视网膜组织中的缺氧来治疗受试者的视网膜疾病的方法。

5. 发明授权

US5722428A Method for producing a posterior vitreous detachment 失效
标题翻译：后玻璃体脱离的方法
公开(公告)号：US5722428A
公开(公告)日：1998-03-03
申请号：US740430
申请日：1996-10-29
申请人： Henry J. Kaplan , Tongalp H. Tezel
发明人： Henry J. Kaplan , Tongalp H. Tezel
IPC分类号： A61F9/007 , A61K9/00 , A61K38/48 , A61B19/00
CPC分类号： A61F9/00736 , A61K38/48 , A61K9/0048
摘要： Methods for enzymatic production of a posterior vitreous detachment are provided. In preferred methods, dispase is used to cleave type IV collagen and fibronectin at the vitreoretinal junction to promote the posterior vitreous detachment. The methods provide for enzymatic treatment in conjunction with intraocular surgery as well as treatments to relieve the blinding complications of certain eye disorders without the need for surgery. Also disclosed are kits for production of a posterior vitreous detachment and devices containing the enzymes useful in the methods.
摘要翻译：提供了用于酶促生产后玻璃体脱离的方法。在优选的方法中，分泌酶用于在玻璃体视网膜结处切割IV型胶原和纤连蛋白以促进玻璃体后脱离。所述方法提供了结合眼内手术的酶处理以及用于减轻某些眼睛疾病的致盲并发症而不需要手术的治疗。还公开了用于生产后玻璃体分离的试剂盒和含有可用于该方法的酶的装置。

6. 发明申请

US20090047258A1 COMPOSITIONS AND METHODS FOR REVERSING AGE-RELATED CHANGES IN EXTRACELLULAR MATRIX PROTEINS 审中-公开
标题翻译：用于逆转细胞基质蛋白中与年龄相关的变化的组合物和方法
公开(公告)号：US20090047258A1
公开(公告)日：2009-02-19
申请号：US11659151
申请日：2005-08-02
申请人： Lucian V. Del Priore , Tongalp Tezel , Henry J. Kaplan
发明人： Lucian V. Del Priore , Tongalp Tezel , Henry J. Kaplan
IPC分类号： A61K35/12 , A61K38/16 , A61P17/00 , A61P27/02 , A61P25/00
CPC分类号： A61Q19/08 , A61K8/365 , A61K8/86 , A61K31/425
摘要： The invention is directed to compositions and methods for reversing age-related changes in extracellular matrix proteins, particularly the collagen framework of basement membranes of various organs. The invention has particular application to age-related changes that impair Retinal Pigment Epithelium (RPE) cell repopulation of human Bruch's membrane.
摘要翻译：本发明涉及用于逆转细胞外基质蛋白的年龄相关变化的组合物和方法，特别是各种器官的基底膜的胶原骨架。本发明特别适用于损害人类Bruch膜的视网膜色素上皮细胞（RPE）细胞再生的年龄相关变化。

7. 发明授权

US07964557B2 Inhibition of wet type age related macular degeneration (AMD) by adiponectin or acrp 30 有权
标题翻译：通过脂联素或acrp抑制湿型年龄相关性黄斑变性（AMD）30
公开(公告)号：US07964557B2
公开(公告)日：2011-06-21
申请号：US11910188
申请日：2006-03-22
申请人： Puran S. Bora , Nalini S. Bora , Henry J. Kaplan
发明人： Puran S. Bora , Nalini S. Bora , Henry J. Kaplan
IPC分类号： A61K38/00 , A61K47/00 , A61K49/00 , A61P27/02 , C07K7/00
CPC分类号： A61K38/2264
摘要： The present invention provides new methods of treating wet type of age related macular degeneration by administering adiponectin (APN) or a functional fragment derived therefrom. One of the pathological complications of age related macular degeneration (AMD) is choroidal angiogenesis or choroidal neovascularization (CNV). The inventors discovered that the level of APN expression is significantly lower in the choroids of the laser-induced mouse model of choroidal angiogenesis or choroidal neovascularization (CNV) than that of the control mice and that administration of recombinant adiponectin (rAPN) or a peptide derived from the globular domain of the intact APN protein to the mouse model of CNV reduced the size of CNV significantly. These studies are the first to demonstrate the inhibitory effect of adiponectin on choroidal angiogenesis and thus provide the basis for treating a condition or disease involving angiogenesis, particularly age related macular degeneration, with administration of adiponectin.
摘要翻译：本发明提供了通过施用脂联素（APN）或其衍生的功能片段治疗湿性年龄相关性黄斑变性的新方法。年龄相关性黄斑变性（AMD）的病理并发症之一是脉络膜血管生成或脉络膜新生血管形成（CNV）。发明人发现激光诱导的脉络膜血管生成或脉络膜新血管形成（CNV）小鼠模型的脉络膜的APN表达水平明显低于对照小鼠，并且施用重组脂联素（rAPN）或肽衍生物从完整的APN蛋白的球状结构域到CNV的小鼠模型显着降低CNV的大小。这些研究首先证明脂联素对脉络膜血管生成的抑制作用，从而提供了通过给予脂联素治疗涉及血管发生，特别是年龄相关性黄斑变性的病症或疾病的基础。

8. 发明申请

US20080221030A1 Inhibition of Wet Type Age Related Macular Degeneration (Amd) by Adiponectin or Acrp 30 有权
标题翻译：脂联素或Acrp抑制湿型年龄相关性黄斑变性（Amd）30
公开(公告)号：US20080221030A1
公开(公告)日：2008-09-11
申请号：US11910188
申请日：2006-03-22
申请人： Puran S. Bora , Nalini S. Bora , Henry J. Kaplan
发明人： Puran S. Bora , Nalini S. Bora , Henry J. Kaplan
IPC分类号： A61K38/17 , C12N5/06 , A61K38/10 , A61P27/02
CPC分类号： A61K38/2264
摘要： The present invention provides new methods of treating wet type of age related macular degeneration by administering adiponectin (APN) or a functional fragment derived therefrom. One of the pathological complications of age related macular degeneration (AMD) is choroidal angiogenesis or choroidal neovascularization (CNV). The inventors discovered that the level of APN expression is significantly lower in the choroids of the laser-induced mouse model of choroidal angiogenesis or choroidal neovascularization (CNV) than that of the control mice and that administration of recombinant adiponectin (rAPN) or a peptide derived from the globular domain of the intact APN protein to the mouse model of CNV reduced the size of CNV significantly. These studies are the first to demonstrate the inhibitory effect of adiponectin on choroidal angiogenesis and thus provide the basis for treating a condition or disease involving angiogenesis, particularly age related macular degeneration, with administration of adiponectin.
摘要翻译：本发明提供了通过施用脂联素（APN）或其衍生的功能片段治疗湿性年龄相关性黄斑变性的新方法。年龄相关性黄斑变性（AMD）的病理并发症之一是脉络膜血管生成或脉络膜新生血管形成（CNV）。发明人发现激光诱导的脉络膜血管生成或脉络膜新血管形成（CNV）小鼠模型的脉络膜的APN表达水平明显低于对照小鼠，并且施用重组脂联素（rAPN）或肽衍生物从完整的APN蛋白的球状结构域到CNV的小鼠模型显着降低CNV的大小。这些研究首先证明脂联素对脉络膜血管生成的抑制作用，从而提供了通过给予脂联素治疗涉及血管发生，特别是年龄相关性黄斑变性的病症或疾病的基础。

9. 发明授权

US07189245B2 Subretinal implantation device and surgical cannulas for use therewith 失效
标题翻译：视网膜下植入装置和与其一起使用的外科插管
公开(公告)号：US07189245B2
公开(公告)日：2007-03-13
申请号：US10367353
申请日：2003-02-14
申请人： Henry J. Kaplan
发明人： Henry J. Kaplan
IPC分类号： A61F9/00
CPC分类号： A61F9/007 , A61F9/00727 , A61F9/08
摘要： An implantation device having a reservoir for holding a solid or semisolid implant and a carrier fluid, wherein the reservoir includes a cannula. The cannula has a tip end and a delivery opening therein both shaped and dimensioned to suit the application. For example, an implant (such as a retinal cell graft) and suitable carrier fluid (such as an aqueous hyaluronic acid solution) can be expressed from the opening into the subretinal space of a recipient eye, provided the cannula is of sufficient length that the tip end can reach the subretinal space while the remainder of the fluid reservoir is external of the eye. Expression of the carrier fluid from the reservoir via the delivery opening expels the implant through the delivery opening. An electromechanically driven plunger apparatus with operator controls is provided in a preferred embodiment.
摘要翻译：一种具有用于保持固体或半固体植入物和载体流体的储存器的植入装置，其中所述储存器包括套管。插管具有尖端和其中的输送开口，其形状和尺寸适于适用。例如，植入物（例如视网膜细胞移植物）和合适的载体流体（例如水性透明质酸溶液）可以从开口进入受体眼的视网膜下空间，只要插管具有足够的长度，尖端可以到达视网膜下空间，而液体储存器的其余部分在眼睛外部。载体流体经由输送口从储存器的表达通过输送口排出植入物。在优选实施例中提供具有操作员控制的机电驱动的柱塞装置。

10. 发明申请

US20100028407A1 LAYERED BIO-ADHESIVE COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译：层状生物胶粘剂组合物及其用途
公开(公告)号：US20100028407A1
公开(公告)日：2010-02-04
申请号：US12298698
申请日：2007-04-24
申请人： Lucian V. Del Priore , Henry J. Kaplan , Tongalp Tezel
发明人： Lucian V. Del Priore , Henry J. Kaplan , Tongalp Tezel
IPC分类号： A61K35/44 , C09J7/02 , A61K9/70 , A61F13/00 , A61P27/02 , A61K47/42 , A61K47/36 , A61K47/34 , A61K47/26 , A61P17/02
CPC分类号： A61L15/40 , A61L15/58 , Y10T428/266
摘要： The invention generally provides compositions and methods for promoting and enhancing wound closure and healing. Specifically, the invention provides a biologic composition which comprises a support layer which serves as transport scaffold, for example made of gelatin, which is coated or impregnated with a bio-adhesive molecule such as rose bengal or glyceraldehyde. The composition can also comprise an artificial or biological matrix, optionally processed (i.e. cleaned and coated with extracellular matrix proteins) to enhance cell attachment and survival. The composition can further comprise a monolayer of epithelial, endothelial cells or mesenchymal cells. The invention provides methods for using the compositions for treating wounds due to disease, trauma or surgery. Specific methods for treating ocular wounds are provided.
摘要翻译：本发明通常提供用于促进和增强伤口闭合和愈合的组合物和方法。具体而言，本发明提供了一种生物组合物，其包含用作运输支架的支撑层，例如由明胶制成，其用诸如玫瑰红或甘油醛的生物粘合剂分子包被或浸渍。组合物还可以包含人造或生物基质，任选地加工（即清洁并涂覆有细胞外基质蛋白质）以增强细胞附着和存活。组合物还可以包含单层的上皮，内皮细胞或间充质细胞。本发明提供了使用该组合物治疗由于疾病，外伤或手术引起的伤口的方法。提供了治疗眼部伤口的具体方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式